Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
about
Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritisBiologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisAdverse effects of biologics: a network meta-analysis and Cochrane overviewAdalimumab for treating rheumatoid arthritisSafety of extended treatment with anakinra in patients with rheumatoid arthritisAssessing the Immunogenicity of BiopharmaceuticalsKey design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an exampleBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisComparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analyAdalimumab for the treatment of rheumatoid arthritisComparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression AnalysisA Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis PatientsImmunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab: A Retrospective Study of a Single Center CohortTNF inhibitor therapy for rheumatoid arthritisBiologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritisIncorporating data from various trial designs into a mixed treatment comparison model.[Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologicals in Germany : real-life clinical practice data].Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project.Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancerRetrospective cohort study of anti-tumor necrosis factor agent use in a veteran populationAdalimumab with Methotrexate in Treatment-Naïve Japanese Patients with Rheumatoid Arthritis at Risk of Progressive Structural Joint Damage: A Postmarketing Observational StudyThe CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology PracticeSafety and immunotoxicity assessment of immunomodulatory monoclonal antibodiesA phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoiThe loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study.Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodiesImpact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational studyEffectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study.Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis.Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.Rationale of using different biological therapies in rheumatoid arthritis.Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.
P2860
Q21134808-626FEF8F-83CD-4F49-9574-9BCE21142B97Q24185797-EDDD0B2A-C4FF-4763-BE51-1DF071DDED30Q24234197-F9E4FE7A-C14A-4417-A181-81C350FB49F9Q24246674-FFBA831F-012A-460F-A3EF-1A70D0873C74Q24675209-B8C7E3C1-958D-44E4-86FB-94F24DAB8511Q26751485-7BC6CF76-1317-43C3-9C3A-521DDEE71F87Q26766368-713E2C92-6F0F-4F17-929F-82B5BF1BE366Q26852235-25A2CE31-E250-4BD1-8DF3-27FB703D2C10Q27694496-8127E973-5298-48EC-97B2-95100E0A86B2Q28282655-541B320B-8C24-4C7A-9150-A52B37D39E56Q28547851-DEBF55BE-BCC5-4411-8FA8-6550C6CA880AQ28551075-C3E26236-ED44-42E5-96E8-613999C09091Q28554222-2CD50222-2DFB-4825-83DE-2A57A51325D9Q28972424-90FDE502-5256-4968-979A-C965B7E4DCA4Q30235341-7F4DB0A3-E483-4C4A-8BFC-0D8C793DE981Q30240183-0D7DB0D9-9BE8-4401-A226-FD328999E2D3Q30240212-B90EAA43-9317-4071-AB5F-738B9268265BQ30574065-3CF9E3EA-EE51-4BA2-ABED-07D6B99D3FC5Q30576366-93EAF30B-1DDA-455D-8A84-396A91BFBBE2Q30594247-666C554E-D6EC-4A10-82A6-E6205B87F38FQ30699616-158DCE05-21A6-4FA6-BD61-A7BEFCB8AEA4Q31169591-D30C243E-C5B9-4433-8950-9E02BCAFF0CBQ33315300-317F8251-C99B-4778-B367-5AA11D1FAC6EQ33328963-DF2ADD33-DF19-4595-A65F-57ED335946F4Q33573112-B0D62565-5794-4AB5-99CC-3A59127E3F0EQ33614221-416E4908-0FAA-46B8-B5C4-D866B7D79A3CQ33667897-DF34F441-12AC-4E23-97C1-E6DC9492FCD4Q33725547-B7F2DCF4-DE77-437F-98FF-839739B183EBQ33775593-2E2D2765-0F44-447C-BBC9-7459494AE034Q33895804-62BC6941-8014-4A2D-A66C-00EE1B64CCADQ33921820-8EFB2135-C6F6-4F53-8186-EBEEF73D15D1Q33923245-5F114113-0538-47AC-B543-9D2AC32F8E52Q33934927-32CFD6EB-CE77-41BE-94D4-DB34F7DEB7DDQ33984823-B39137E9-AC3E-4D88-A278-418CF8816FE1Q34012929-16CC0E26-5C76-4048-B101-07D778956E15Q34076916-710DAA12-ED53-4A8B-B70D-B77E0483304DQ34083054-D4DD71E1-1013-4763-8D5E-8F68FC4237FCQ34118958-B6A78E95-5656-4AA1-9B12-A25DB5F4EA44Q34153073-F3B72CB4-E744-4151-A273-E07AA1196CF2Q34343286-8F78182A-0B1F-4100-9A5D-4504F6CB5DD0
P2860
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Efficacy and safety of adalimu ...... tic drug treatment has failed.
@ast
Efficacy and safety of adalimu ...... tic drug treatment has failed.
@en
Efficacy and safety of adalimu ...... tic drug treatment has failed.
@en-gb
type
label
Efficacy and safety of adalimu ...... tic drug treatment has failed.
@ast
Efficacy and safety of adalimu ...... tic drug treatment has failed.
@en
Efficacy and safety of adalimu ...... tic drug treatment has failed.
@en-gb
prefLabel
Efficacy and safety of adalimu ...... tic drug treatment has failed.
@ast
Efficacy and safety of adalimu ...... tic drug treatment has failed.
@en
Efficacy and safety of adalimu ...... tic drug treatment has failed.
@en-gb
P2093
P2860
P356
P1476
Efficacy and safety of adalimu ...... tic drug treatment has failed.
@en
P2093
A S Russell
J W Bijlsma
L B A van de Putte
M Dougados
P2860
P304
P356
10.1136/ARD.2003.013052
P407
P577
2004-05-01T00:00:00Z
P5875
P6179
1006545154